ESMO 2023 | NIBIT-M2: 7-year outcomes and QoL analysis in melanoma patients

Georgina V. Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia, discusses the seven-year efficacy outcomes and health-related quality-of-life (HRQoL) analyses of the Phase III NIBIT-M2 (NCT02460068) trial. The study evaluated the efficacy of fotemustine (Arm A) versus the combination of fotesmustine and ipilimumab (Arm B) or the combination of ipilimumab and nivolumab (Arm C) in patients with metastatic melanoma with brain metastasis. The seven-year overall survival (OS) rate was 10% in Arm A, 10.3% in Arm B, and 42.8% in Arm C. The seven-year intracranial progression-free survival (iPFS) rates were 4.3%, 7.7% and 28.6% in Arms A, B and C respectively. HRQoL was preserved in all treatment arm. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.